Skip to main content
Erschienen in: Journal of Neuro-Oncology 3/2018

23.05.2018 | Topic Review

The clinical importance of medulloblastoma extent of resection: a systematic review

verfasst von: Eric M. Thompson, Alexa Bramall, James E. Herndon II, Michael D. Taylor, Vijay Ramaswamy

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Although the majority of current medulloblastoma adjuvant therapy protocols treat patients with ≥ 1.5 cm2 residual tumor as high risk with increased craniospinal irradiation, the true prognostic significance of extent of resection (EOR) in medulloblastoma is unknown.

Objectives

We sought to synthesize the body of literature on EOR and survival to determine if a definitive association exists.

Data sources/eligibility criteria

A PubMed search was conducted for the terms “medulloblastoma” combined with “extent of resection,” “overall survival,” “progression free survival,” “gross total resection,” “near total resection,” “partial resection,” or “subtotal resection.” Studies that performed a statistical analysis of EOR and survival were included.

Results

Sixteen articles including 1489 patients found a statistically significant association between EOR and survival, 20 articles including 2335 patients did not find a significant association between EOR and survival, and 14 articles including 2950 patients had mixed results. The three articles that accounted for molecular subgroup found varying associations between EOR and progression free survival, while no association was found between EOR and overall survival.

Limitations

This review is limited by inconsistent definitions of EOR, the retrospective nature of the articles analyzed, and infrequent use of multivariate statistical analyses.

Conclusions

The prognostic importance of EOR for medulloblastoma is unclear and warrants re-evaluation, particularly in the context of molecular subgrouping.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Cavalli FMG, Remke M, Rampasek L, Peacock J, Shih DJH, Luu B, Garzia L, Torchia J, Nor C, Morrissy AS, Agnihotri S, Thompson YY, Kuzan-Fischer CM, Farooq H, Isaev K, Daniels C, Cho BK, Kim SK, Wang KC, Lee JY, Grajkowska WA, Perek-Polnik M, Vasiljevic A, Faure-Conter C, Jouvet A, Giannini C, Nageswara Rao AA, Li KKW, Ng HK, Eberhart CG, Pollack IF, Hamilton RL, Gillespie GY, Olson JM, Leary S, Weiss WA, Lach B, Chambless LB, Thompson RC, Cooper MK, Vibhakar R, Hauser P, van Veelen MC, Kros JM, French PJ, Ra YS, Kumabe T, Lopez-Aguilar E, Zitterbart K, Sterba J, Finocchiaro G, Massimino M, Van Meir EG, Osuka S, Shofuda T, Klekner A, Zollo M, Leonard JR, Rubin JB, Jabado N, Albrecht S, Mora J, Van Meter TE, Jung S, Moore AS, Hallahan AR, Chan JA, Tirapelli DPC, Carlotti CG, Fouladi M, Pimentel J, Faria CC, Saad AG, Massimi L, Liau LM, Wheeler H, Nakamura H, Elbabaa SK, Perezpena-Diazconti M, de Leon FCP, Robinson S, Zapotocky M, Lassaletta A, Huang A, Hawkins CE, Tabori U, Bouffet E, Bartels U, Dirks PB, Rutka JT, Bader GD, Reimand J, Goldenberg A, Ramaswamy V, Taylor MD (2017) Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell 31(6):737–754. https://doi.org/10.1016/j.ccell.2017.05.005 CrossRefPubMedPubMedCentral Cavalli FMG, Remke M, Rampasek L, Peacock J, Shih DJH, Luu B, Garzia L, Torchia J, Nor C, Morrissy AS, Agnihotri S, Thompson YY, Kuzan-Fischer CM, Farooq H, Isaev K, Daniels C, Cho BK, Kim SK, Wang KC, Lee JY, Grajkowska WA, Perek-Polnik M, Vasiljevic A, Faure-Conter C, Jouvet A, Giannini C, Nageswara Rao AA, Li KKW, Ng HK, Eberhart CG, Pollack IF, Hamilton RL, Gillespie GY, Olson JM, Leary S, Weiss WA, Lach B, Chambless LB, Thompson RC, Cooper MK, Vibhakar R, Hauser P, van Veelen MC, Kros JM, French PJ, Ra YS, Kumabe T, Lopez-Aguilar E, Zitterbart K, Sterba J, Finocchiaro G, Massimino M, Van Meir EG, Osuka S, Shofuda T, Klekner A, Zollo M, Leonard JR, Rubin JB, Jabado N, Albrecht S, Mora J, Van Meter TE, Jung S, Moore AS, Hallahan AR, Chan JA, Tirapelli DPC, Carlotti CG, Fouladi M, Pimentel J, Faria CC, Saad AG, Massimi L, Liau LM, Wheeler H, Nakamura H, Elbabaa SK, Perezpena-Diazconti M, de Leon FCP, Robinson S, Zapotocky M, Lassaletta A, Huang A, Hawkins CE, Tabori U, Bouffet E, Bartels U, Dirks PB, Rutka JT, Bader GD, Reimand J, Goldenberg A, Ramaswamy V, Taylor MD (2017) Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell 31(6):737–754. https://​doi.​org/​10.​1016/​j.​ccell.​2017.​05.​005 CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, Eberhart CG, Parsons DW, Rutkowski S, Gajjar A, Ellison DW, Lichter P, Gilbertson RJ, Pomeroy SL, Kool M, Pfister SM (2012) Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 123(4):465–472. https://doi.org/10.1007/s00401-011-0922-z CrossRefPubMed Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, Eberhart CG, Parsons DW, Rutkowski S, Gajjar A, Ellison DW, Lichter P, Gilbertson RJ, Pomeroy SL, Kool M, Pfister SM (2012) Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 123(4):465–472. https://​doi.​org/​10.​1007/​s00401-011-0922-z CrossRefPubMed
5.
Zurück zum Zitat Thompson EM, Hielscher T, Bouffet E, Remke M, Luu B, Gururangan S, McLendon RE, Bigner DD, Lipp ES, Perreault S, Cho YJ, Grant G, Kim SK, Lee JY, Rao AA, Giannini C, Li KK, Ng HK, Yao Y, Kumabe T, Tominaga T, Grajkowska WA, Perek-Polnik M, Low DC, Seow WT, Chang KT, Mora J, Pollack IF, Hamilton RL, Leary S, Moore AS, Ingram WJ, Hallahan AR, Jouvet A, Fevre-Montange M, Vasiljevic A, Faure-Conter C, Shofuda T, Kagawa N, Hashimoto N, Jabado N, Weil AG, Gayden T, Wataya T, Shalaby T, Grotzer M, Zitterbart K, Sterba J, Kren L, Hortobagyi T, Klekner A, Laszlo B, Pocza T, Hauser P, Schuller U, Jung S, Jang WY, French PJ, Kros JM, van Veelen ML, Massimi L, Leonard JR, Rubin JB, Vibhakar R, Chambless LB, Cooper MK, Thompson RC, Faria CC, Carvalho A, Nunes S, Pimentel J, Fan X, Muraszko KM, Lopez-Aguilar E, Lyden D, Garzia L, Shih DJ, Kijima N, Schneider C, Adamski J, Northcott PA, Kool M, Jones DT, Chan JA, Nikolic A, Garre ML, Van Meir EG, Osuka S, Olson JJ, Jahangiri A, Castro BA, Gupta N, Weiss WA, Moxon-Emre I, Mabbott DJ, Lassaletta A, Hawkins CE, Tabori U, Drake J, Kulkarni A, Dirks P, Rutka JT, Korshunov A, Pfister SM, Packer RJ, Ramaswamy V, Taylor MD (2016) Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncol 17(4):484–495. https://doi.org/10.1016/S1470-2045(15)00581-1 CrossRefPubMedPubMedCentral Thompson EM, Hielscher T, Bouffet E, Remke M, Luu B, Gururangan S, McLendon RE, Bigner DD, Lipp ES, Perreault S, Cho YJ, Grant G, Kim SK, Lee JY, Rao AA, Giannini C, Li KK, Ng HK, Yao Y, Kumabe T, Tominaga T, Grajkowska WA, Perek-Polnik M, Low DC, Seow WT, Chang KT, Mora J, Pollack IF, Hamilton RL, Leary S, Moore AS, Ingram WJ, Hallahan AR, Jouvet A, Fevre-Montange M, Vasiljevic A, Faure-Conter C, Shofuda T, Kagawa N, Hashimoto N, Jabado N, Weil AG, Gayden T, Wataya T, Shalaby T, Grotzer M, Zitterbart K, Sterba J, Kren L, Hortobagyi T, Klekner A, Laszlo B, Pocza T, Hauser P, Schuller U, Jung S, Jang WY, French PJ, Kros JM, van Veelen ML, Massimi L, Leonard JR, Rubin JB, Vibhakar R, Chambless LB, Cooper MK, Thompson RC, Faria CC, Carvalho A, Nunes S, Pimentel J, Fan X, Muraszko KM, Lopez-Aguilar E, Lyden D, Garzia L, Shih DJ, Kijima N, Schneider C, Adamski J, Northcott PA, Kool M, Jones DT, Chan JA, Nikolic A, Garre ML, Van Meir EG, Osuka S, Olson JJ, Jahangiri A, Castro BA, Gupta N, Weiss WA, Moxon-Emre I, Mabbott DJ, Lassaletta A, Hawkins CE, Tabori U, Drake J, Kulkarni A, Dirks P, Rutka JT, Korshunov A, Pfister SM, Packer RJ, Ramaswamy V, Taylor MD (2016) Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncol 17(4):484–495. https://​doi.​org/​10.​1016/​S1470-2045(15)00581-1 CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Ramaswamy V, Remke M, Bouffet E, Bailey S, Clifford SC, Doz F, Kool M, Dufour C, Vassal G, Milde T, Witt O, von Hoff K, Pietsch T, Northcott PA, Gajjar A, Robinson GW, Padovani L, Andre N, Massimino M, Pizer B, Packer R, Rutkowski S, Pfister SM, Taylor MD, Pomeroy SL (2016) Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol 31(6):821–831. https://doi.org/10.1007/s00401-016-1569-6 CrossRef Ramaswamy V, Remke M, Bouffet E, Bailey S, Clifford SC, Doz F, Kool M, Dufour C, Vassal G, Milde T, Witt O, von Hoff K, Pietsch T, Northcott PA, Gajjar A, Robinson GW, Padovani L, Andre N, Massimino M, Pizer B, Packer R, Rutkowski S, Pfister SM, Taylor MD, Pomeroy SL (2016) Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol 31(6):821–831. https://​doi.​org/​10.​1007/​s00401-016-1569-6 CrossRef
7.
Zurück zum Zitat Albright AL, Sposto R, Holmes E, Zeltzer PM, Finlay JL, Wisoff JH, Berger MS, Packer RJ, Pollack IF (2000) Correlation of neurosurgical subspecialization with outcomes in children with malignant brain tumors. Neurosurgery 47(4):879–885 (discussion 885–877)CrossRefPubMed Albright AL, Sposto R, Holmes E, Zeltzer PM, Finlay JL, Wisoff JH, Berger MS, Packer RJ, Pollack IF (2000) Correlation of neurosurgical subspecialization with outcomes in children with malignant brain tumors. Neurosurgery 47(4):879–885 (discussion 885–877)CrossRefPubMed
8.
Zurück zum Zitat Cochrane DD, Gustavsson B, Poskitt KP, Steinbok P, Kestle JR (1994) The surgical and natural morbidity of aggressive resection for posterior fossa tumors in childhood. Pediatr Neurosurg 20(1):19–29CrossRefPubMed Cochrane DD, Gustavsson B, Poskitt KP, Steinbok P, Kestle JR (1994) The surgical and natural morbidity of aggressive resection for posterior fossa tumors in childhood. Pediatr Neurosurg 20(1):19–29CrossRefPubMed
10.
11.
Zurück zum Zitat Pollack IF, Polinko P, Albright AL, Towbin R, Fitz C (1995) Mutism and pseudobulbar symptoms after resection of posterior fossa tumors in children: incidence and pathophysiology. Neurosurgery 37(5):885–893CrossRefPubMed Pollack IF, Polinko P, Albright AL, Towbin R, Fitz C (1995) Mutism and pseudobulbar symptoms after resection of posterior fossa tumors in children: incidence and pathophysiology. Neurosurgery 37(5):885–893CrossRefPubMed
15.
Zurück zum Zitat Bourne JP, Geyer R, Berger M, Griffin B, Milstein J (1992) The prognostic significance of postoperative residual contrast enhancement on CT scan in pediatric patients with medulloblastoma. J Neurooncol 14(3):263–270CrossRefPubMed Bourne JP, Geyer R, Berger M, Griffin B, Milstein J (1992) The prognostic significance of postoperative residual contrast enhancement on CT scan in pediatric patients with medulloblastoma. J Neurooncol 14(3):263–270CrossRefPubMed
17.
Zurück zum Zitat Giralt J, Sanchez de Toledo J, Moraga F, Poch JM, Gallego S, Rosello J, Maldonado X, Prats J (1996) Improving survival of medulloblastoma: results in two groups of patients. Oncology 53(1):38–42CrossRefPubMed Giralt J, Sanchez de Toledo J, Moraga F, Poch JM, Gallego S, Rosello J, Maldonado X, Prats J (1996) Improving survival of medulloblastoma: results in two groups of patients. Oncology 53(1):38–42CrossRefPubMed
18.
Zurück zum Zitat Hughes EN, Shillito J, Sallan SE, Loeffler JS, Cassady JR, Tarbell NJ (1988) Medulloblastoma at the joint center for radiation therapy between 1968 and 1984. The influence of radiation dose on the patterns of failure and survival. Cancer 61(10):1992–1998CrossRefPubMed Hughes EN, Shillito J, Sallan SE, Loeffler JS, Cassady JR, Tarbell NJ (1988) Medulloblastoma at the joint center for radiation therapy between 1968 and 1984. The influence of radiation dose on the patterns of failure and survival. Cancer 61(10):1992–1998CrossRefPubMed
19.
Zurück zum Zitat Jenkin D, Goddard K, Armstrong D, Becker L, Berry M, Chan H, Doherty M, Greenberg M, Hendrick B, Hoffman H et al (1990) Posterior fossa medulloblastoma in childhood: treatment results and a proposal for a new staging system. Int J Radiat Oncol Biol Phys 19(2):265–274CrossRefPubMed Jenkin D, Goddard K, Armstrong D, Becker L, Berry M, Chan H, Doherty M, Greenberg M, Hendrick B, Hoffman H et al (1990) Posterior fossa medulloblastoma in childhood: treatment results and a proposal for a new staging system. Int J Radiat Oncol Biol Phys 19(2):265–274CrossRefPubMed
20.
Zurück zum Zitat Lannering B, Rutkowski S, Doz F, Pizer B, Gustafsson G, Navajas A, Massimino M, Reddingius R, Benesch M, Carrie C, Taylor R, Gandola L, Bjork-Eriksson T, Giralt J, Oldenburger F, Pietsch T, Figarella-Branger D, Robson K, Forni M, Clifford SC, Warmuth-Metz M, von Hoff K, Faldum A, Mosseri V, Kortmann R (2012) Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol 30(26):3187–3193. https://doi.org/10.1200/jco.2011.39.8719 CrossRefPubMed Lannering B, Rutkowski S, Doz F, Pizer B, Gustafsson G, Navajas A, Massimino M, Reddingius R, Benesch M, Carrie C, Taylor R, Gandola L, Bjork-Eriksson T, Giralt J, Oldenburger F, Pietsch T, Figarella-Branger D, Robson K, Forni M, Clifford SC, Warmuth-Metz M, von Hoff K, Faldum A, Mosseri V, Kortmann R (2012) Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol 30(26):3187–3193. https://​doi.​org/​10.​1200/​jco.​2011.​39.​8719 CrossRefPubMed
23.
24.
Zurück zum Zitat Stavrou T, Bromley CM, Nicholson HS, Byrne J, Packer RJ, Goldstein AM, Reaman GH (2001) Prognostic factors and secondary malignancies in childhood medulloblastoma. J Pediatr Hematol Oncol 23(7):431–436CrossRefPubMed Stavrou T, Bromley CM, Nicholson HS, Byrne J, Packer RJ, Goldstein AM, Reaman GH (2001) Prognostic factors and secondary malignancies in childhood medulloblastoma. J Pediatr Hematol Oncol 23(7):431–436CrossRefPubMed
25.
Zurück zum Zitat Sure U, Bertalanffy H, Isenmann S, Brandner S, Berghorn WJ, Seeger W, Aguzzi A (1995) Secondary manifestation of medulloblastoma: metastases and local recurrences in 66 patients. Acta Neurochir 136(3–4):117–126CrossRefPubMed Sure U, Bertalanffy H, Isenmann S, Brandner S, Berghorn WJ, Seeger W, Aguzzi A (1995) Secondary manifestation of medulloblastoma: metastases and local recurrences in 66 patients. Acta Neurochir 136(3–4):117–126CrossRefPubMed
26.
Zurück zum Zitat Tait DM, Thornton-Jones H, Bloom HJ, Lemerle J, Morris-Jones P (1990) Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer 26(4):464–469CrossRefPubMed Tait DM, Thornton-Jones H, Bloom HJ, Lemerle J, Morris-Jones P (1990) Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer 26(4):464–469CrossRefPubMed
27.
Zurück zum Zitat Tomita T, Yasue M, Engelhard HH, McLone DG, Gonzalez-Crussi F, Bauer KD (1988) Flow cytometric DNA analysis of medulloblastoma. Prognostic implication of aneuploidy. Cancer 61(4):744–749CrossRefPubMed Tomita T, Yasue M, Engelhard HH, McLone DG, Gonzalez-Crussi F, Bauer KD (1988) Flow cytometric DNA analysis of medulloblastoma. Prognostic implication of aneuploidy. Cancer 61(4):744–749CrossRefPubMed
30.
Zurück zum Zitat Harisiadis L, Chang CH (1977) Medulloblastoma in children: a correlation between staging and results of treatment. Int J Radiat Oncol Biol Phys 2(9–10):833–841CrossRefPubMed Harisiadis L, Chang CH (1977) Medulloblastoma in children: a correlation between staging and results of treatment. Int J Radiat Oncol Biol Phys 2(9–10):833–841CrossRefPubMed
36.
Zurück zum Zitat Garre ML, Cama A, Bagnasco F, Morana G, Giangaspero F, Brisigotti M, Gambini C, Forni M, Rossi A, Haupt R, Nozza P, Barra S, Piatelli G, Viglizzo G, Capra V, Bruno W, Pastorino L, Massimino M, Tumolo M, Fidani P, Dallorso S, Schumacher RF, Milanaccio C, Pietsch T (2009) Medulloblastoma variants: age-dependent occurrence and relation to Gorlin syndrome–a new clinical perspective. Clin Cancer Res 15(7):2463–2471. https://doi.org/10.1158/1078-0432.CCR-08-2023 CrossRefPubMed Garre ML, Cama A, Bagnasco F, Morana G, Giangaspero F, Brisigotti M, Gambini C, Forni M, Rossi A, Haupt R, Nozza P, Barra S, Piatelli G, Viglizzo G, Capra V, Bruno W, Pastorino L, Massimino M, Tumolo M, Fidani P, Dallorso S, Schumacher RF, Milanaccio C, Pietsch T (2009) Medulloblastoma variants: age-dependent occurrence and relation to Gorlin syndrome–a new clinical perspective. Clin Cancer Res 15(7):2463–2471. https://​doi.​org/​10.​1158/​1078-0432.​CCR-08-2023 CrossRefPubMed
37.
Zurück zum Zitat Grabenbauer GG, Beck JD, Erhardt J, Seegenschmiedt MH, Seyer H, Thierauf P, Sauer R (1996) Postoperative radiotherapy of medulloblastoma. Impact of radiation quality on treatment outcome. Am J Clin Oncol 19(1):73–77CrossRefPubMed Grabenbauer GG, Beck JD, Erhardt J, Seegenschmiedt MH, Seyer H, Thierauf P, Sauer R (1996) Postoperative radiotherapy of medulloblastoma. Impact of radiation quality on treatment outcome. Am J Clin Oncol 19(1):73–77CrossRefPubMed
38.
Zurück zum Zitat Herms J, Neidt I, Luscher B, Sommer A, Schurmann P, Schroder T, Bergmann M, Wilken B, Probst-Cousin S, Hernaiz-Driever P, Behnke J, Hanefeld F, Pietsch T, Kretzschmar HA (2000) C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer 89(5):395–402CrossRefPubMed Herms J, Neidt I, Luscher B, Sommer A, Schurmann P, Schroder T, Bergmann M, Wilken B, Probst-Cousin S, Hernaiz-Driever P, Behnke J, Hanefeld F, Pietsch T, Kretzschmar HA (2000) C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer 89(5):395–402CrossRefPubMed
39.
Zurück zum Zitat Johnston DL, Keene D, Bartels U, Carret AS, Crooks B, Eisenstat DD, Fryer C, Lafay-Cousin L, Larouche V, Moghrabi A, Wilson B, Zelcer S, Silva M, Brossard J, Bouffet E (2009) Medulloblastoma in children under the age of three years: a retrospective Canadian review. J Neurooncol 94(1):51–56. https://doi.org/10.1007/s11060-009-9799-2 CrossRefPubMed Johnston DL, Keene D, Bartels U, Carret AS, Crooks B, Eisenstat DD, Fryer C, Lafay-Cousin L, Larouche V, Moghrabi A, Wilson B, Zelcer S, Silva M, Brossard J, Bouffet E (2009) Medulloblastoma in children under the age of three years: a retrospective Canadian review. J Neurooncol 94(1):51–56. https://​doi.​org/​10.​1007/​s11060-009-9799-2 CrossRefPubMed
42.
Zurück zum Zitat Lal P, Nagar YS, Kumar S, Singh S, Maria Das KJ, Narayan SL, Kumar R, Jain VK, Ayyagari S (2002) Medulloblastomas: clinical profile, treatment techniques and outcome—an institutional experience. Indian J Cancer 39(3):97–105PubMed Lal P, Nagar YS, Kumar S, Singh S, Maria Das KJ, Narayan SL, Kumar R, Jain VK, Ayyagari S (2002) Medulloblastomas: clinical profile, treatment techniques and outcome—an institutional experience. Indian J Cancer 39(3):97–105PubMed
45.
Zurück zum Zitat Nasr A, Al-Ghamdy H (2004) The prognostic impact of additional chemotherapy to radiation therapy for postoperative management of pediatric medulloblastoma. J Egypt Natl Cancer Inst 16(4):195–201 Nasr A, Al-Ghamdy H (2004) The prognostic impact of additional chemotherapy to radiation therapy for postoperative management of pediatric medulloblastoma. J Egypt Natl Cancer Inst 16(4):195–201
46.
Zurück zum Zitat Taylor RE, Bailey CC, Robinson K, Weston CL, Ellison D, Ironside J, Lucraft H, Gilbertson R, Tait DM, Walker DA, Pizer BL, Imeson J, Lashford LS, International Society of Paediatric O, United Kingdom Children’s Cancer Study G (2003) Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children’s Cancer Study Group PNET-3 Study. J Clin Oncol 21(8):1581–1591. https://doi.org/10.1200/JCO.2003.05.116 CrossRefPubMed Taylor RE, Bailey CC, Robinson K, Weston CL, Ellison D, Ironside J, Lucraft H, Gilbertson R, Tait DM, Walker DA, Pizer BL, Imeson J, Lashford LS, International Society of Paediatric O, United Kingdom Children’s Cancer Study G (2003) Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children’s Cancer Study Group PNET-3 Study. J Clin Oncol 21(8):1581–1591. https://​doi.​org/​10.​1200/​JCO.​2003.​05.​116 CrossRefPubMed
47.
Zurück zum Zitat Woodburn RT, Azzarelli B, Montebello JF, Goss IE (2001) Intense p53 staining is a valuable prognostic indicator for poor prognosis in medulloblastoma/central nervous system primitive neuroectodermal tumors. J Neurooncol 52(1):57–62CrossRefPubMed Woodburn RT, Azzarelli B, Montebello JF, Goss IE (2001) Intense p53 staining is a valuable prognostic indicator for poor prognosis in medulloblastoma/central nervous system primitive neuroectodermal tumors. J Neurooncol 52(1):57–62CrossRefPubMed
48.
Zurück zum Zitat Pietsch T, Schmidt R, Remke M, Korshunov A, Hovestadt V, Jones DT, Felsberg J, Kaulich K, Goschzik T, Kool M, Northcott PA, von Hoff K, von Bueren AO, Friedrich C, Mynarek M, Skladny H, Fleischhack G, Taylor MD, Cremer F, Lichter P, Faldum A, Reifenberger G, Rutkowski S, Pfister SM (2014) Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. Acta Neuropathol 128(1):137–149. https://doi.org/10.1007/s00401-014-1276-0 CrossRefPubMedPubMedCentral Pietsch T, Schmidt R, Remke M, Korshunov A, Hovestadt V, Jones DT, Felsberg J, Kaulich K, Goschzik T, Kool M, Northcott PA, von Hoff K, von Bueren AO, Friedrich C, Mynarek M, Skladny H, Fleischhack G, Taylor MD, Cremer F, Lichter P, Faldum A, Reifenberger G, Rutkowski S, Pfister SM (2014) Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. Acta Neuropathol 128(1):137–149. https://​doi.​org/​10.​1007/​s00401-014-1276-0 CrossRefPubMedPubMedCentral
49.
Zurück zum Zitat Dhall G, Grodman H, Ji L, Sands S, Gardner S, Dunkel IJ, McCowage GB, Diez B, Allen JC, Gopalan A, Cornelius AS, Termuhlen A, Abromowitch M, Sposto R, Finlay JL (2008) Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the “Head Start” I and II protocols. Pediatr Blood Cancer 50(6):1169–1175. https://doi.org/10.1002/pbc.21525 CrossRefPubMed Dhall G, Grodman H, Ji L, Sands S, Gardner S, Dunkel IJ, McCowage GB, Diez B, Allen JC, Gopalan A, Cornelius AS, Termuhlen A, Abromowitch M, Sposto R, Finlay JL (2008) Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the “Head Start” I and II protocols. Pediatr Blood Cancer 50(6):1169–1175. https://​doi.​org/​10.​1002/​pbc.​21525 CrossRefPubMed
50.
Zurück zum Zitat Albright AL, Wisoff JH, Zeltzer PM, Boyett JM, Rorke LB, Stanley P (1996) Effects of medulloblastoma resections on outcome in children: a report from the Children’s Cancer Group. Neurosurgery 38(2):265–271CrossRefPubMed Albright AL, Wisoff JH, Zeltzer PM, Boyett JM, Rorke LB, Stanley P (1996) Effects of medulloblastoma resections on outcome in children: a report from the Children’s Cancer Group. Neurosurgery 38(2):265–271CrossRefPubMed
53.
Zurück zum Zitat Danjoux CE, Jenkin RD, McLaughlin J, Grimard L, Gaspar LE, Dar AR, Fisher B, Whitton AC, Kraus V, Springer CD, et al. (1996) Childhood medulloblastoma in Ontario, 1977–1987: population-based results. Med Pediatr Oncol 26 (1):1–9CrossRefPubMed Danjoux CE, Jenkin RD, McLaughlin J, Grimard L, Gaspar LE, Dar AR, Fisher B, Whitton AC, Kraus V, Springer CD, et al. (1996) Childhood medulloblastoma in Ontario, 1977–1987: population-based results. Med Pediatr Oncol 26 (1):1–9CrossRefPubMed
54.
Zurück zum Zitat Grill J, Sainte-Rose C, Jouvet A, Gentet JC, Lejars O, Frappaz D, Doz F, Rialland X, Pichon F, Bertozzi AI, Chastagner P, Couanet D, Habrand JL, Raquin MA, Le Deley MC, Kalifa C, French Society of Paediatric O (2005) Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol 6(8):573–580. https://doi.org/10.1016/S1470-2045(05)70252-7 CrossRefPubMed Grill J, Sainte-Rose C, Jouvet A, Gentet JC, Lejars O, Frappaz D, Doz F, Rialland X, Pichon F, Bertozzi AI, Chastagner P, Couanet D, Habrand JL, Raquin MA, Le Deley MC, Kalifa C, French Society of Paediatric O (2005) Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol 6(8):573–580. https://​doi.​org/​10.​1016/​S1470-2045(05)70252-7 CrossRefPubMed
55.
Zurück zum Zitat Hershatter BW, Halperin EC, Cox EB (1986) Medulloblastoma: the Duke University Medical Center experience. Int J Radiat Oncol Biol Phys 12(10):1771–1777CrossRefPubMed Hershatter BW, Halperin EC, Cox EB (1986) Medulloblastoma: the Duke University Medical Center experience. Int J Radiat Oncol Biol Phys 12(10):1771–1777CrossRefPubMed
56.
Zurück zum Zitat Khafaga Y, Kandil AE, Jamshed A, Hassounah M, DeVol E, Gray AJ (1996) Treatment results for 149 medulloblastoma patients from one institution. Int J Radiat Oncol Biol Phys 35(3):501–506CrossRefPubMed Khafaga Y, Kandil AE, Jamshed A, Hassounah M, DeVol E, Gray AJ (1996) Treatment results for 149 medulloblastoma patients from one institution. Int J Radiat Oncol Biol Phys 35(3):501–506CrossRefPubMed
57.
Zurück zum Zitat Michiels EM, Heikens J, Jansen MJ, Oldenburger F, Voute T (2000) Are clinical parameters valuable prognostic factors in childhood primitive neuroectodermal tumors? A multivariate analysis of 105 cases. Radiother Oncol Oncology 54(3):229–238CrossRef Michiels EM, Heikens J, Jansen MJ, Oldenburger F, Voute T (2000) Are clinical parameters valuable prognostic factors in childhood primitive neuroectodermal tumors? A multivariate analysis of 105 cases. Radiother Oncol Oncology 54(3):229–238CrossRef
58.
Zurück zum Zitat Packer RJ, Boyett JM, Janss AJ, Stavrou T, Kun L, Wisoff J, Russo C, Geyer R, Phillips P, Kieran M, Greenberg M, Goldman S, Hyder D, Heideman R, Jones-Wallace D, August GP, Smith SH, Moshang T (2001) Growth hormone replacement therapy in children with medulloblastoma: use and effect on tumor control. J Clin Oncol 19(2):480–487. https://doi.org/10.1200/jco.2001.19.2.480 CrossRefPubMed Packer RJ, Boyett JM, Janss AJ, Stavrou T, Kun L, Wisoff J, Russo C, Geyer R, Phillips P, Kieran M, Greenberg M, Goldman S, Hyder D, Heideman R, Jones-Wallace D, August GP, Smith SH, Moshang T (2001) Growth hormone replacement therapy in children with medulloblastoma: use and effect on tumor control. J Clin Oncol 19(2):480–487. https://​doi.​org/​10.​1200/​jco.​2001.​19.​2.​480 CrossRefPubMed
61.
Zurück zum Zitat Weil MD, Lamborn K, Edwards MS, Wara WM (1998) Influence of a child’s sex on medulloblastoma outcome. JAMA 279(18):1474–1476CrossRefPubMed Weil MD, Lamborn K, Edwards MS, Wara WM (1998) Influence of a child’s sex on medulloblastoma outcome. JAMA 279(18):1474–1476CrossRefPubMed
62.
Zurück zum Zitat Zeltzer PM, Boyett JM, Finlay JL, Albright AL, Rorke LB, Milstein JM, Allen JC, Stevens KR, Stanley P, Li H, Wisoff JH, Geyer JR, McGuire-Cullen P, Stehbens JA, Shurin SB, Packer RJ (1999) Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol 17(3):832–845. https://doi.org/10.1200/jco.1999.17.3.832 CrossRefPubMed Zeltzer PM, Boyett JM, Finlay JL, Albright AL, Rorke LB, Milstein JM, Allen JC, Stevens KR, Stanley P, Li H, Wisoff JH, Geyer JR, McGuire-Cullen P, Stehbens JA, Shurin SB, Packer RJ (1999) Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol 17(3):832–845. https://​doi.​org/​10.​1200/​jco.​1999.​17.​3.​832 CrossRefPubMed
63.
Zurück zum Zitat Esbenshade AJ, Kocak M, Hershon L, Rousseau P, Decarie JC, Shaw S, Burger P, Friedman HS, Gajjar A, Moghrabi A (2017) A Phase II feasibility study of oral etoposide given concurrently with radiotherapy followed by dose intensive adjuvant chemotherapy for children with newly diagnosed high-risk medulloblastoma (protocol POG 9631): A report from the Children’s Oncology Group. Pediatr Blood Cancer. https://doi.org/10.1002/pbc.26373 CrossRefPubMed Esbenshade AJ, Kocak M, Hershon L, Rousseau P, Decarie JC, Shaw S, Burger P, Friedman HS, Gajjar A, Moghrabi A (2017) A Phase II feasibility study of oral etoposide given concurrently with radiotherapy followed by dose intensive adjuvant chemotherapy for children with newly diagnosed high-risk medulloblastoma (protocol POG 9631): A report from the Children’s Oncology Group. Pediatr Blood Cancer. https://​doi.​org/​10.​1002/​pbc.​26373 CrossRefPubMed
64.
Zurück zum Zitat Packer RJ, Gajjar A, Vezina G, Rorke-Adams L, Burger PC, Robertson PL, Bayer L, LaFond D, Donahue BR, Marymont MH, Muraszko K, Langston J, Sposto R (2006) Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 24(25):4202–4208. https://doi.org/10.1200/jco.2006.06.4980 CrossRefPubMed Packer RJ, Gajjar A, Vezina G, Rorke-Adams L, Burger PC, Robertson PL, Bayer L, LaFond D, Donahue BR, Marymont MH, Muraszko K, Langston J, Sposto R (2006) Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 24(25):4202–4208. https://​doi.​org/​10.​1200/​jco.​2006.​06.​4980 CrossRefPubMed
65.
Zurück zum Zitat Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, Woo S, Wheeler G, Ahern V, Krasin MJ, Fouladi M, Broniscer A, Krance R, Hale GA, Stewart CF, Dauser R, Sanford RA, Fuller C, Lau C, Boyett JM, Wallace D, Gilbertson RJ (2006) Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 7(10):813–820. https://doi.org/10.1016/s1470-2045(06)70867-1 CrossRefPubMed Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, Woo S, Wheeler G, Ahern V, Krasin MJ, Fouladi M, Broniscer A, Krance R, Hale GA, Stewart CF, Dauser R, Sanford RA, Fuller C, Lau C, Boyett JM, Wallace D, Gilbertson RJ (2006) Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 7(10):813–820. https://​doi.​org/​10.​1016/​s1470-2045(06)70867-1 CrossRefPubMed
66.
Zurück zum Zitat Xu H, Robinson GW, Huang J, Lim JY, Zhang H, Bass JK, Broniscer A, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Fisher M, Cohn R, Yamashita T, Teitz T, Zuo J, Onar-Thomas A, Gajjar A, Stewart CF, Yang JJ (2015) Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nat Genet 47(3):263–266. https://doi.org/10.1038/ng.3217 CrossRefPubMedPubMedCentral Xu H, Robinson GW, Huang J, Lim JY, Zhang H, Bass JK, Broniscer A, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Fisher M, Cohn R, Yamashita T, Teitz T, Zuo J, Onar-Thomas A, Gajjar A, Stewart CF, Yang JJ (2015) Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nat Genet 47(3):263–266. https://​doi.​org/​10.​1038/​ng.​3217 CrossRefPubMedPubMedCentral
68.
71.
Zurück zum Zitat Albert FK, Forsting M, Sartor K, Adams HP, Kunze S (1994) Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 34(1):45–60. (discussion 60–41)PubMed Albert FK, Forsting M, Sartor K, Adams HP, Kunze S (1994) Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 34(1):45–60. (discussion 60–41)PubMed
Metadaten
Titel
The clinical importance of medulloblastoma extent of resection: a systematic review
verfasst von
Eric M. Thompson
Alexa Bramall
James E. Herndon II
Michael D. Taylor
Vijay Ramaswamy
Publikationsdatum
23.05.2018
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 3/2018
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-018-2906-5

Weitere Artikel der Ausgabe 3/2018

Journal of Neuro-Oncology 3/2018 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Neurologie

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.